ArticleTranslational andrology and urology2026
Sacubitril/valsartan improves nocturia in hypertensive patients: a pilot study.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nocturia is associated with falls, reduced quality of life (QOL), and sleep disturbances, yet remains underdiagnosed and undertreated. Its multifactorial etiology includes reduced bladder capacity, nocturnal polyuria (NP), and comorbid conditions like hypertension. While antihypertensive therapies have been linked to nocturia, the impact of newer agents remains unclear. This study investigated whether sacubitril/valsartan (Sac/Val), a novel angiotensin receptor-neprilysin inhibitor used for refractory hypertension, could improve nocturia. Sac/Val's unique natriuretic and diuretic effects may influence NP through modulation of neurohormonal pathways. Methods: Eighteen hypertensive patients with nocturia (mean age 66.7 years) were evaluated over 12 weeks. The primary outcome was change in nighttime voiding frequency, assessed via voiding diaries. Secondary outcomes included Pittsburgh Sleep Quality Index-Japanese Version (PSQI-J), Nocturia Quality of Life Questionnaire (N-QOL), Overactive Bladder Symptom Score (OABSS), International Prostate Symptom Score (IPSS), and overall QOL. Results: Results showed a significant reduction in nighttime voids (from 3.31 to 2.10) and nocturnal polyuria index (NPi) (from 48.1% to 39.7%). Sleep quality (PSQI-J) and nocturia-related QOL (N-QOL) also improved. No significant changes were observed in IPSS or general QOL scores, while OABSS nocturia scores decreased. This is the first study to demonstrate Sac/Val's potential to improve nocturia, likely via its effects on NP and blood pressure (BP). Conclusions: The present study suggests that cardiovascular disease (CVD) may be an often-overlooked factor in the cause of nocturia. Therefore, a multidisciplinary approach is essential for the management of NP, and there is a need to promote collaboration between specialties with an emphasis on developing more patient-specific treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.